

## Annual Flash Report (unaudited)

Fiscal Year ended March 31, 2014

### Sales of Major Products

Supplemental Data

For information purpose only

(Note) All amounts are rounded off to the nearest hundred million yen.

		2014			Year ending
		Results	Increase/Decrease		March
					31,2015
					Forecast
<b>Glactiv</b>	Agent for type II diabetes	¥ 357	¥ +9	+2.6 %	¥ 320
<b>Opalmon</b>	Circulatory system agent	325	△ 14	△ 4.2 %	285
<b>Onon</b>	Agent for bronchial asthma and allergic rhinitis	135	△ 27	△ 16.6 %	105
<b>Recalbon</b>	Agent for osteoporosis	111	+34	+45.0 %	120
<b>Emend/Proemend</b>	Agent for Chemotherapy-induced nausea and vomiting	88	+8	+10.5 %	105
<b>Foipan</b>	Agent for chronic pancreatitis and postoperative reflux esophagitis	80	△ 8	△ 8.7 %	70
<b>Kinedak</b>	Agent for diabetic peripheral neuropathy	74	△ 13	△ 14.5 %	60
<b>Onon dry syrup</b>	Agent for pediatric bronchial asthma and allergic rhinitis	69	△ 4	△ 6.0 %	60
<b>Staybla</b>	Agent for overactive bladder (pollakiuria and urinary incontinence)	65	+1	+1.0 %	65
<b>Rivastach</b>	Agent for Alzheimer's disease	64	+25	+63.8 %	80
<b>Onoact</b>	Agent for tachyarrhythmia during and post operation	44	+7	+18.8 %	60
<b>Elaspol</b>	Agent for acute lung injury associated with SIRS	35	△ 4	△ 9.1 %	30
<b>Orencia SC</b>	Agent for rheumatoid arthritis	8	—	—	30

Note: 1 Sales of products are shown in a gross sales basis.

2 Orencia SC was launched in Fiscal 2013, and year-on-year changes in value and percentage are therefore not available.